Spacelabs Healthcare Partners With Masimo to Bring Advanced Measurements to Spacelabs Patient Monitors
Spacelabs Healthcare, a division of OSI Systems, has announced an extension of its partnership with Masimo to integrate advanced patient monitoring technologies into Spacelabs multi-parameter monitors. The collaboration will include SET pulse oximetry, NomoLine capnography, and other innovative monitoring solutions.
Both companies aim to enhance patient care by providing deeper insights into patients' physiological conditions, thereby improving outcomes for healthcare providers and patients alike.
- Extended partnership with Masimo enhances product offerings in patient monitoring.
- Integration of advanced technologies may lead to improved patient outcomes.
- None.
Spacelabs Healthcare®, a division of OSI Systems, Inc. (the “Company” or “OSI Systems”), and Masimo today announced that they have extended their partnership in patient monitoring to integrate SET® pulse oximetry, NomoLine® capnography, rainbow SET® Pulse CO-Oximetry, SedLine® brain function monitoring, and O3® regional oximetry into select Spacelabs multi-parameter monitors.
“We are pleased to extend our partnership with Masimo as an important element of our mission to empower the care team to achieve superior outcomes,” said Spacelabs President Shalabh Chandra. “Masimo’s suite of advanced measurements, combined with Spacelabs’ innovative patient monitoring systems, helps us present a clear picture of the patient’s condition, prompting caregivers to take the right action at the right time.”
Jon Coleman, President of Worldwide OEM Sales and Global Health at Masimo, added, “We are pleased to have the opportunity to partner with Spacelabs to bring so many of our advanced parameters to hospitals equipped with their innovative patient monitors, helping them provide the best care possible. Together, we can help clinicians gain more insight into their patients’ physiological status—ultimately helping them improve outcomes.”
About Spacelabs Healthcare
Spacelabs Healthcare (www.spacelabshealthcare.com), a division of OSI Systems, Inc., is a provider of medical equipment and services, including solutions for patient monitoring and connectivity, non-invasive cardiology, and supplies and accessories selling to hospitals, clinics, and physician offices. The Company has offices in the United States, United Kingdom, Canada, France, Germany, and Italy, and distributors in more than 100 countries around the world.
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Masimo’s mission is to improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications.
About OSI Systems
OSI Systems (NASDAQ: OSIS) is a vertically integrated designer and manufacturer of specialized electronic systems and components for critical applications in the homeland security, healthcare, defense, and aerospace industries. The Company combines more than 40 years of electronics engineering and manufacturing experience with offices and production facilities in more than a dozen countries to implement a strategy of expansion into selective end product markets. For more information on OSI Systems or its subsidiary companies, visit www.osi-systems.com. News Filter: OSIS-G
Forward-Looking Statements – OSI Systems
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to OSI Systems’ current expectations, beliefs, and projections concerning matters that are not historical facts. Forward-looking statements are not guarantees of future performance and involve uncertainties, risks, assumptions, and contingencies, many of which are outside OSI Systems’ control and which may cause actual results to differ materially from those described in or implied by any forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are based on currently available information and speak only as of the date on which they are made. OSI Systems assumes no obligation to update any forward-looking statement made in this press release that becomes untrue because of subsequent events, new information, or otherwise, except to the extent it is required to do so in connection with its ongoing requirements under Federal securities laws. For a further discussion of factors that could cause OSI Systems’ future results to differ materially from any forward-looking statements, see the section entitled "Risk Factors" in OSI Systems’ most recently filed Annual Report on Form 10-K and other risks described therein and in documents subsequently filed by OSI Systems from time to time with the Securities and Exchange Commission.
Forward-Looking Statements - Masimo
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of SET®, rainbow SET®, NomoLine®, SedLine®, and O3®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including SET®, rainbow SET®, NomoLine, SedLine, and O3, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005074/en/
FAQ
What is the recent partnership announcement between OSI Systems and Masimo?
What technologies are included in the Spacelabs and Masimo partnership?
When was the partnership between OSI Systems and Masimo announced?
What are the potential benefits of the Masimo and Spacelabs partnership for healthcare?
How does the partnership affect OSI Systems' stock performance?
